A Phase 1 interventional study of GBT021601 in Sickle Cell Disease, sponsored by Pfizer. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-08.
Sponsored by Pfizer · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Anemia, Sickle Cell by Pfizer — 1 open to participants now, 1 under way, 1 of them phase 3. Anemia, Sickle Cell · Pfizer.
Among the 32 studies in Anemia, Sickle Cell by Pfizer, this one is the 20th largest by enrollment of the 27 interventional ones that give a count, is one of 7 that started in 2022, is one of 10 in phase 1, and was the 30th registered.
1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.
Browse Anemia, Sickle Cell studies →1 of the 32 studies in Anemia, Sickle Cell by Pfizer is open now, in 7 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Brazil, India and 4 more countries
Ages 12+
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 5 · Phase 3 11 · Phase 4 3
First in 2014; this study’s year is marked. 7 started in 2022.
This study's enrollment of 9 is below the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 52 across the 27 interventional studies, 216 across the 3 observational. Of the 28 that completed or were terminated, 19 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 32 studies in Anemia, Sickle Cell by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An Open-label Study of GBT021601 in 8 to 10 healthy male or female participants to evaluate the absorption, distribution, metabolism, and excretion (ADME) of GBT021601.
This is an open-label Study administering GBT021601 as a single oral dose of 200 mg in healthy participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
open-label GBT021601
Drug: GBT021601
Single oral dose of 200 mg GBT021601, containing \~74 kBq (\~2 µCi) of \[14C\]-GBT021601
GBT021601 Concentration in Whole Blood and Plasma at Predose
Time frame: Predose (within 60 minutes prior to GBT021601 dosing)
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at Predose
Data reported in microgram equivalent per milliliter (mcgEq/mL).
Time frame: Predose (within 60 minutes prior to 14C-GBT021601 dosing)
GBT021601 Concentration in Whole Blood and Plasma at 0.25 Hours
Time frame: 0.25 hours post dosing on Day 1
14C-GBT021601 Total Radioactivity Concentrations in Whole Blood and Plasma at 0.25 Hours
Time frame: 0.25 hours post dosing on Day 1
GBT021601 Concentration in Whole Blood and Plasma at 0.50 Hours
Time frame: 0.50 hours post dosing on Day 1
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 0.50 Hours
Time frame: 0.50 hours post dosing on Day 1
GBT021601 Concentration in Whole Blood and Plasma at 1 Hours
Time frame: 1 hours post dosing on Day 1
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 1 Hours
Time frame: 1 hours post dosing on Day 1
GBT021601 Concentration in Whole Blood and Plasma at 2 Hours
Time frame: 2 hours post dosing on Day 1
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 2 Hours
Time frame: 2 hours post dosing on Day 1
GBT021601 Concentration in Whole Blood and Plasma at 3 Hours
Time frame: 3 hours post dosing on Day 1
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 3 Hours
Time frame: 3 hours post dosing on Day 1
GBT021601 Concentration in Whole Blood and Plasma at 4 Hours
Time frame: 4 hours post dosing on Day 1
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 4 Hours
Time frame: 4 hours post dosing on Day 1
GBT021601 Concentration in Whole Blood and Plasma at 6 Hours
Time frame: 6 hours post dosing on Day 1
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 6 Hours
Time frame: 6 hours post dosing on Day 1
GBT021601 Concentration in Whole Blood and Plasma at 8 Hours
Time frame: 8 hours post dosing on Day 1
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 8 Hours
Time frame: 8 hours post dosing on Day 1
GBT021601 Concentration in Whole Blood and Plasma at 12 Hours
Time frame: 12 hours post dosing on Day 1
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 12 Hours
Time frame: 12 hours post dosing on Day 1
GBT021601 Concentration in Whole Blood and Plasma at 24 Hours
Time frame: 24 hours post dosing on Day 1
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 24 Hours
Time frame: 24 hours post dosing on Day 1
GBT021601 Concentration in Whole Blood and Plasma at 48 Hours
Time frame: 48 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 48 Hours
Time frame: 48 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 72 Hours
Time frame: 72 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 72 Hours
Time frame: 72 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 96 Hours
Time frame: 96 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 96 Hours
Time frame: 96 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 144 Hours
Time frame: 144 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 144 Hours
Time frame: 144 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 168 Hours
Time frame: 168 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 168 Hours
Time frame: 168 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 312 Hours
Time frame: 312 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 312 Hours
Time frame: 312 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 480 Hours
Time frame: 480 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 480 Hours
Time frame: 480 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 648 Hours
Time frame: 648 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 648 Hours
Time frame: 648 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 816 Hours
Time frame: 816 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 816 Hours
Time frame: 816 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 984 Hours
Time frame: 984 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 984 Hours
Time frame: 984 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 1320 Hours
Time frame: 1320 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 1320 Hours
Time frame: 1320 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 1656 Hours
Time frame: 1656 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 1656 Hours
Time frame: 1656 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 1992 Hours
Time frame: 1992 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 1992 Hours
Time frame: 1992 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 2328 Hours
Time frame: 2328 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 2328 Hours
Time frame: 2328 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 2664 Hours
Time frame: 2664 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 2664 Hours
Time frame: 2664 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 3240 Hours
Time frame: 3240 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 3240 Hours
Time frame: 3240 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 3576 Hours
Time frame: 3576 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 3576 Hours
Time frame: 3576 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 4248 Hours
Time frame: 4248 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 4248 Hours
Time frame: 4248 hours post dosing
GBT021601 Concentration in Whole Blood and Plasma at 4920 Hours
Time frame: 4920 hours post dosing
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 4920 Hours
Time frame: 4920 hours post dosing
Cumulative Amount of [14C]-GBT021601 Total Radioactivity Excreted in Urine and Feces
Data are reported as aggregate of all scheduled time points.
Time frame: Day 1 (prior to dosing), after dosing from 0-6 hours, 6-12 hrs, 12-24 hrs postdose for urine, 24-hr intervals up to Day 29; 816 hrs , 984 hrs, 1320 hrs, 1656 hrs, 1992 hrs, 2328 hrs, 2664 hrs, 3240 hrs, 3576 hrs, 4248 hrs, and 4920 hrs post-dose
Cumulative Fraction of [14C]-GBT021601 Total Radioactivity Excreted in Urine and Feces
Data are reported as aggregate of all scheduled time points.
Time frame: Day 1 (prior to dosing), after dosing from 0-6 hours, 6-12 hrs, 12-24 hrs postdose for urine, 24-hr intervals up to Day 29; 816 hrs , 984 hrs, 1320 hrs, 1656 hrs, 1992 hrs, 2328 hrs, 2664 hrs, 3240 hrs, 3576 hrs, 4248 hrs, and 4920 hrs post-dose
Area Under the Plasma Concentration-Time Curve From Time Zero (0) to 24 Hours (AUC0-24) of GBT021601 in Whole Blood and Plasma
Area under the plasma concentration-time curve up to 24 hours post dose. Data reported in Hour\*microgram/millimeter (h\*mcg/mL).
Time frame: Day 1 (prior to dosing) at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours
Area Under the Plasma Concentration-Time Curve From Time Zero (0) to 24 Hours (AUC0-24) of 14C-GBT021601 in Whole Blood and Plasma
Area under the plasma concentration-time curve up to 24 hours postdose. Data reported in hour\*microgram equivalent/milliliter (h\*mcgEq/mL).
Time frame: Day 1 (prior to dosing) at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours
Area Under the Concentration-Time From Time Zero to the Last Measurable Concentration (AUC0-last) of GBT021601 in Whole Blood and Plasma
Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Area Under the Concentration-Time From Time Zero to the Last Measurable Concentration (AUC0-last) of 14C-GBT021601 in Whole Blood and Plasma
Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of GBT021601 in Whole Blood and Plasma
Area under the plasma concentration-time curve from time 0 to infinity calculated as: AUC0-inf=AUC0-t+Clast/kel, where Clast is the last measurable plasma concentration.
Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of 14C-GBT021601 in Whole Blood and Plasma
Area under the plasma concentration-time curve from time 0 to infinity calculated as: AUC0-inf=AUC0-t+Clast/kel, where Clast is the last measurable plasma concentration and Kel is apparent terminal elimination rate constant.
Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Maximum Observed Concentration (Cmax) of GBT021601 in Whole Blood and Plasma
Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Maximum Observed Concentration (Cmax) of 14C-GBT021601 in Whole Blood and Plasma
Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Time to Attain Maximum Observed Concentration (Tmax) of GBT021601 in Whole Blood and Plasma
Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Time to Attain Maximum Observed Concentration (Tmax) of 14C-GBT021601 in Whole Blood and Plasma
Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Apparent Terminal Elimination Half-Life (t1/2) of GBT021601 in Whole Blood and Plasma
Apparent terminal elimination half-life, calculated as 0.693/kel where kel is Apparent terminal elimination rate constant.
Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Apparent Terminal Elimination Half-Life (t1/2) of 14C-GBT021601 in Whole Blood and Plasma
Apparent terminal elimination half-life, calculated as 0.693/kel where kel is Apparent terminal elimination rate constant.
Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Renal Clearance (CLR) of GBT021601 and 14C-GBT021601 in Urine
Renal clearance was calculated as CLR = Ae0-inf/AUC0-inf. Where Ae indicates Cumulative amount of drug excreted and AUC0-inf indicates Area under the plasma concentration-time curve from time 0 to infinity.
Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Apparent Volume of Distribution at Terminal Phase (Vz/F) of GBT021601 in Whole Blood and Plasma
Apparent volume of distribution at terminal phase, calculated as: (CL/F) Apparent total clearance, calculated as dose/AUC0-inf/Kel.
Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Apparent Volume of Distribution at Terminal Phase (Vz/F) of 14C-GBT021601 in Whole Blood and Plasma
Apparent volume of distribution at terminal phase, calculated as: (CL/F) Apparent total clearance, calculated as dose/AUC0-inf/Kel.
Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Apparent Total Clearance (CL/F) of GBT021601 in Whole Blood and Plasma
Apparent total clearance, calculated as dose/AUC0-inf.
Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Apparent Total Clearance (CL/F) of 14C-GBT021601 in Whole Blood and Plasma
Apparent total clearance, calculated as dose/AUC0-inf.
Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 0-6 Hours
Time frame: 0-6 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 6-12 Hours
Time frame: 6-12 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 12-24 Hours
Time frame: 12-24 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 0-24 Hours
Time frame: 0-24 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 24 Hours
Time frame: 24 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 48 Hours
Time frame: 48 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 72 Hours
Time frame: 72 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 96 Hours
Time frame: 96 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 120 Hours
Time frame: 120 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 144 Hours
Time frame: 144 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 168 Hours
Time frame: 168 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 192 Hours
Time frame: 192 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 216 Hours
Time frame: 216 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 240 Hours
Time frame: 240 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 264 Hours
Time frame: 264 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 288 Hours
Time frame: 288 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 312 Hours
Time frame: 312 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 336 Hours
Time frame: 336 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 360 Hours
Time frame: 360 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 384 Hours
Time frame: 384 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 408 Hours
Time frame: 408 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 432 Hours
Time frame: 432 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 456 Hours
Time frame: 456 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 480 Hours
Time frame: 480 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 504 Hours
Time frame: 504 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 528 Hours
Time frame: 528 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 552 Hours
Time frame: 552 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 576 Hours
Time frame: 576 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 600 Hours
Time frame: 600 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 624 Hours
Time frame: 624 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 648 Hours
Time frame: 648 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 816 Hours
Time frame: 816 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 984 Hours
Time frame: 984 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 1320 Hours
Time frame: 1320 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 1656 Hours
Time frame: 1656 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 1992 Hours
Time frame: 1992 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 2328 Hours
Time frame: 2328 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 2664 Hours
Time frame: 2664 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 3240 Hours
Time frame: 3240 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 3576 Hours
Time frame: 3576 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 4248 Hours
Time frame: 4248 hours post dose
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 4920 Hours
Time frame: 4920 hours post dose
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An Adverse event (AE) was any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. TEAEs were those which occurred (or worsened) after the dose of study drug during the on-treatment period, defined as the period after the dose of study drug and through the minimum of (Study Day 57, study discontinuation).
Time frame: From Day 1 up to maximum of Day 57
Number of Participants With Clinically Significant Laboratory Values
Blood and urine samples was collected for clinical laboratory assessments. Clinical Laboratory Values included Clinical chemistry: alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin (total, direct, and indirect), blood urea nitrogen, calcium, chloride, creatinine, gamma glutamyl transferase, glucose, lactate dehydrogenase, magnesium, phosphorus, potassium, sodium, total protein, and uric acid. Hematology: leukocytes, erythrocytes, hematocrit, Hb, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count (ie, thrombocytes), RBC count, and white blood cell count etc. Urinalysis: determination of pH and specific gravity, and presence of bilirubin, blood, glucose, ketones, nitrite, protein, leukocytes, and urobilinogen etc. Coagulation, Serology, Drug and alcohol screen and Pregnancy test. Clinical significance was judged by investigator.
Time frame: Day 1 of dosing to Day 207
Number of Participants With Clinically Significant Vital Signs Values
Systolic and diastolic blood pressure and pulse was recorded after the participant had rested for at least 5 minutes in the supine position. Body temperature and respiratory rate was also measured. Clinical significance was judged by investigator.
Time frame: Day 1 of dosing to Day 207
Number of Participants With Clinically Significant ECG Values
Standard 12-lead ECGs were performed after the participant had rested quietly for more than 5 minutes in a supine position utilizing an ECG machine that was equipped with computer-based interval measurements. The following measurement was recorded: the heart rate (of \<45 or \>100 beats per minute (BPM) , PR interval, QT interval, QT interval corrected using Fridericia's formula (QTcF) of \>450 msec for males and \>470 msec for females, and QRS duration. Any cardiac rhythm other than sinus rhythm that was interpreted by the Investigator was clinically significant.
Time frame: Day 1
Number of Participants With Clinically Significant Physical Examination Values
Physical Examination test included body weight and height. physical examination was conducted at screening. Clinical significance was judged by investigator.
Time frame: Screening (-28 Day to -2 Day, day with respect to dosing)
A total of 9 participants were enrolled in this study.
| Milestone | GBT021601+[14C]-GBT021601 |
|---|---|
| Started | 9 |
| Completed | 6 |
| Not completed | 3 |
| Withdrew: Withdrawal by subject | 3 |
| Microgram/ milliliter (mcg/mL) | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole blood | NA ± NA |
| Plasma | NA ± NA |
Data reported in microgram equivalent per milliliter (mcgEq/mL).
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole blood | 0 ± 0 |
| Plasma | 0 ± 0 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole blood | 6.368 ± 5.4178 |
| Plasma | 0.46267 ± 0.373675 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 5.8206 ± 4.64396 |
| Plasma | 0.84819 ± 0.595349 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 17.33 ± 4.122 |
| Plasma | 1.2338 ± 0.37097 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 16.45 ± 4.348 |
| Plasma | 2.345 ± 0.6467 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 29.37 ± 4.520 |
| Plasma | 1.433 ± 0.1997 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 27.24 ± 4.590 |
| Plasma | 2.913 ± 0.4117 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 31.92 ± 6.544 |
| Plasma | 0.9228 ± 0.21798 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 29.52 ± 5.586 |
| Plasma | 2.089 ± 0.4195 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 31.92 ± 6.544 |
| Plasma | 0.5974 ± 0.13629 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 29.78 ± 5.540 |
| Plasma | 1.502 ± 0.2753 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 34.96 ± 6.738 |
| Plasma | 0.4539 ± 0.14820 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 31.23 ± 6.483 |
| Plasma | 1.2243 ± 0.32688 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 34.84 ± 7.996 |
| Plasma | 0.3013 ± 0.07405 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 31.51 ± 7.104 |
| Plasma | 0.8534 ± 0.19276 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 36.00 ± 8.979 |
| Plasma | 0.2267 ± 0.06210 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 31.53 ± 8.016 |
| Plasma | 0.6592 ± 0.13795 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 36.49 ± 10.844 |
| Plasma | 0.1986 ± 0.05917 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 32.95 ± 7.459 |
| Plasma | 0.5064 ± 0.11455 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 37.53 ± 8.855 |
| Plasma | 0.1479 ± 0.03685 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 33.62 ± 7.819 |
| Plasma | 0.3256 ± 0.06395 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 37.39 ± 9.904 |
| Plasma | 0.1402 ± 0.02718 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 33.29 ± 7.384 |
| Plasma | 0.2207 ± 0.03853 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 35.41 ± 7.642 |
| Plasma | 0.1377 ± 0.03011 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 31.38 ± 6.475 |
| Plasma | 0.1861 ± 0.03361 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 34.67 ± 7.339 |
| Plasma | 0.12923 ± 0.026617 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 30.62 ± 5.839 |
| Plasma | 0.1670 ± 0.03204 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 32.48 ± 7.257 |
| Plasma | 0.11038 ± 0.016657 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 28.81 ± 5.988 |
| Plasma | 0.1434 ± 0.02345 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 32.91 ± 7.603 |
| Plasma | 0.12189 ± 0.020679 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 27.33 ± 5.329 |
| Plasma | 0.1471 ± 0.03267 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 26.59 ± 5.353 |
| Plasma | 0.11109 ± 0.024207 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 23.44 ± 3.976 |
| Plasma | 0.1274 ± 0.01847 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 22.38 ± 3.991 |
| Plasma | 0.08271 ± 0.014586 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 19.30 ± 2.743 |
| Plasma | 0.09706 ± 0.010952 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 18.71 ± 3.597 |
| Plasma | 0.07343 ± 0.011345 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 16.32 ± 2.161 |
| Plasma | 0.08224 ± 0.007987 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 15.20 ± 1.553 |
| Plasma | 0.06894 ± 0.011486 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 12.93 ± 1.403 |
| Plasma | 0.08084 ± 0.005649 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 12.60 ± 1.715 |
| Plasma | 0.05919 ± 0.006786 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 11.087 ± 1.4815 |
| Plasma | 0.06646 ± 0.005689 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 8.772 ± 1.1434 |
| Plasma | 0.03829 ± 0.003602 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 7.599 ± 1.1109 |
| Plasma | 0.04387 ± 0.004128 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 6.253 ± 0.9576 |
| Plasma | 0.02809 ± 0.005965 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 5.528 ± 1.0078 |
| Plasma | 0.02835 ± 0.004387 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 4.283 ± 0.7310 |
| Plasma | 0.01881 ± 0.003921 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 3.667 ± 0.5431 |
| Plasma | 0.01909 ± 0.004378 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 2.997 ± 0.6994 |
| Plasma | 0.01407 ± 0.007193 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 2.677 ± 0.5212 |
| Plasma | 0.013250 ± 0.0042927 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 2.290 ± 0.4786 |
| Plasma | NA ± NA |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 2.064 ± 0.3699 |
| Plasma | 0.008206 ± 0.0031073 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 1.1523 ± 0.38725 |
| Plasma | NA ± NA |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 0.9463 ± 0.30792 |
| Plasma | NA ± NA |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 0.6097 ± 0.52801 |
| Plasma | NA ± NA |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 0.6733 ± 0.24908 |
| Plasma | NA ± NA |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | NA ± NA |
| Plasma | NA ± NA |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 0.2745 ± 0.14637 |
| Plasma | NA ± NA |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | NA ± NA |
| Plasma | NA ± NA |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 0.2330 ± NA |
| Plasma | NA ± NA |
Data are reported as aggregate of all scheduled time points.
| milligram equivalents (mgEq) | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 95.23 ± 10.153 |
| Feces | 81.38 ± 12.668 |
Data are reported as aggregate of all scheduled time points.
| Percentage of administered drug | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 47.24 ± 5.036 |
| Feces | 40.37 ± 6.284 |
Area under the plasma concentration-time curve up to 24 hours post dose. Data reported in Hour\*microgram/millimeter (h\*mcg/mL).
| h*mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 824.1 ± 22.3 |
| Plasma | 7.393 ± 20.0 |
Area under the plasma concentration-time curve up to 24 hours postdose. Data reported in hour\*microgram equivalent/milliliter (h\*mcgEq/mL).
| h*mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole Blood | 741.8 ± 21.3 |
| Plasma | 17.92 ± 19.2 |
| h*mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole blood | 31481.7 ± 20.9 |
| Plasma | 130.35 ± 16.7 |
| h*mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole blood | 27609.6 ± 18.5 |
| Plasma | 165.7 ± 13.1 |
Area under the plasma concentration-time curve from time 0 to infinity calculated as: AUC0-inf=AUC0-t+Clast/kel, where Clast is the last measurable plasma concentration.
| h*mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole blood | 35290.5 ± 12.1 |
| Plasma | 150.7 ± 10.8 |
Area under the plasma concentration-time curve from time 0 to infinity calculated as: AUC0-inf=AUC0-t+Clast/kel, where Clast is the last measurable plasma concentration and Kel is apparent terminal elimination rate constant.
| h*mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole blood | 30636.1 ± 10.5 |
| Plasma | 179.1 ± 8.8 |
| mcg/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole blood | 40.06 ± 27.1 |
| Plasma | 1.468 ± 14.0 |
| mcgEq/mL | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole blood | 34.05 ± 20.8 |
| Plasma | 2.950 ± 12.5 |
| Hour (h) | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole blood | 24.000 (8.00 to 72.03) |
| Plasma | 1.000 (0.50 to 1.00) |
| Hour | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole blood | 24.000 (4.00 to 48.00) |
| Plasma | 1.000 (0.50 to 1.00) |
Apparent terminal elimination half-life, calculated as 0.693/kel where kel is Apparent terminal elimination rate constant.
| Hour | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole blood | 647.8 ± 84.51 |
| Plasma | 707.1 ± 112.32 |
Apparent terminal elimination half-life, calculated as 0.693/kel where kel is Apparent terminal elimination rate constant.
| Hour | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole blood | 654.7 ± 92.46 |
| Plasma | 588.9 ± 109.92 |
Renal clearance was calculated as CLR = Ae0-inf/AUC0-inf. Where Ae indicates Cumulative amount of drug excreted and AUC0-inf indicates Area under the plasma concentration-time curve from time 0 to infinity.
| Liter/hour (L/h) | GBT021601+[14C]-GBT021601 |
|---|---|
| Renal Clearance (CLR) of GBT021601 and 14C-GBT021601 in Urine | 0.2755 ± 12.6 |
Apparent volume of distribution at terminal phase, calculated as: (CL/F) Apparent total clearance, calculated as dose/AUC0-inf/Kel.
| Liter (L) | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole blood | 5.175 ± 18.3 |
| Plasma | 1300.6 ± 15.5 |
Apparent volume of distribution at terminal phase, calculated as: (CL/F) Apparent total clearance, calculated as dose/AUC0-inf/Kel.
| Liter | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole blood | 5.972 ± 15.9 |
| Plasma | 906.1 ± 14.4 |
Apparent total clearance, calculated as dose/AUC0-inf.
| L/h | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole blood | 0.005713 ± 12.1 |
| Plasma | 1.338 ± 10.8 |
Apparent total clearance, calculated as dose/AUC0-inf.
| L/h | GBT021601+[14C]-GBT021601 |
|---|---|
| Whole blood | 0.006580 ± 10.5 |
| Plasma | 1.1258 ± 8.8 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 13.123 ± 4.5812 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 16.611 ± 4.2333 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 19.70 ± 4.021 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Feces | 0.060486 ± 0.1389173 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 23.19 ± 4.305 |
| Feces | 24.25 ± 9.726 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 25.50 ± 4.727 |
| Feces | 33.17 ± 7.021 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 27.55 ± 5.112 |
| Feces | 35.06 ± 8.909 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 29.35 ± 5.504 |
| Feces | 37.31 ± 8.103 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 30.97 ± 5.791 |
| Feces | 40.54 ± 4.600 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 32.88 ± 6.151 |
| Feces | 39.51 ± 8.832 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 34.82 ± 6.438 |
| Feces | 40.87 ± 7.673 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 36.72 ± 6.695 |
| Feces | 44.39 ± 5.139 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 38.48 ± 6.926 |
| Feces | 43.09 ± 9.219 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 40.22 ± 7.197 |
| Feces | 43.54 ± 8.212 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 41.99 ± 7.402 |
| Feces | 45.31 ± 8.482 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 43.65 ± 7.589 |
| Feces | 44.72 ± 7.324 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 45.06 ± 7.759 |
| Feces | 46.29 ± 9.018 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 46.50 ± 7.899 |
| Feces | 50.24 ± 5.880 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 47.92 ± 8.085 |
| Feces | 48.56 ± 8.315 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 49.41 ± 8.242 |
| Feces | 52.20 ± 6.116 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 50.87 ± 8.418 |
| Feces | 49.97 ± 9.261 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 52.24 ± 8.469 |
| Feces | 50.84 ± 9.215 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 53.59 ± 8.564 |
| Feces | 53.99 ± 6.398 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 54.81 ± 8.616 |
| Feces | 52.89 ± 9.678 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 56.00 ± 8.649 |
| Feces | 53.22 ± 9.709 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 57.15 ± 8.734 |
| Feces | 56.23 ± 6.834 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 58.19 ± 8.845 |
| Feces | 55.14 ± 9.750 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 59.25 ± 9.013 |
| Feces | 55.39 ± 9.766 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 60.20 ± 9.159 |
| Feces | 58.26 ± 7.116 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 61.13 ± 9.230 |
| Feces | 57.17 ± 9.867 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 62.18 ± 9.313 |
| Feces | 59.51 ± 8.648 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 67.24 ± 8.848 |
| Feces | 62.99 ± 11.632 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 74.37 ± 9.568 |
| Feces | 67.30 ± 11.537 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 83.07 ± 9.068 |
| Feces | 72.95 ± 12.135 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 89.48 ± 9.168 |
| Feces | 76.42 ± 13.642 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 93.46 ± 9.065 |
| Feces | 79.01 ± 14.557 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 92.85 ± 7.592 |
| Feces | 84.14 ± 15.744 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 100.08 ± 12.033 |
| Feces | 59.86 ± 0.613 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 98.36 ± 10.969 |
| Feces | 69.27 ± 13.344 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 98.96 ± 11.161 |
| Feces | 69.62 ± 13.175 |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 93.30 ± 3.569 |
| Feces | 85.10 ± NA |
| mgEq | GBT021601+[14C]-GBT021601 |
|---|---|
| Urine | 96.31 ± NA |
| Feces | 63.87 ± NA |
An Adverse event (AE) was any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. TEAEs were those which occurred (or worsened) after the dose of study drug during the on-treatment period, defined as the period after the dose of study drug and through the minimum of (Study Day 57, study discontinuation).
| Participants | GBT021601+[14C]-GBT021601 |
|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 4 |
Blood and urine samples was collected for clinical laboratory assessments. Clinical Laboratory Values included Clinical chemistry: alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin (total, direct, and indirect), blood urea nitrogen, calcium, chloride, creatinine, gamma glutamyl transferase, glucose, lactate dehydrogenase, magnesium, phosphorus, potassium, sodium, total protein, and uric acid. Hematology: leukocytes, erythrocytes, hematocrit, Hb, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count (ie, thrombocytes), RBC count, and white blood cell count etc. Urinalysis: determination of pH and specific gravity, and presence of bilirubin, blood, glucose, ketones, nitrite, protein, leukocytes, and urobilinogen etc. Coagulation, Serology, Drug and alcohol screen and Pregnancy test. Clinical significance was judged by investigator.
| Participants | GBT021601+[14C]-GBT021601 |
|---|---|
| Number of Participants With Clinically Significant Laboratory Values | 0 |
Systolic and diastolic blood pressure and pulse was recorded after the participant had rested for at least 5 minutes in the supine position. Body temperature and respiratory rate was also measured. Clinical significance was judged by investigator.
| Participants | GBT021601+[14C]-GBT021601 |
|---|---|
| Number of Participants With Clinically Significant Vital Signs Values | 0 |
Standard 12-lead ECGs were performed after the participant had rested quietly for more than 5 minutes in a supine position utilizing an ECG machine that was equipped with computer-based interval measurements. The following measurement was recorded: the heart rate (of \<45 or \>100 beats per minute (BPM) , PR interval, QT interval, QT interval corrected using Fridericia's formula (QTcF) of \>450 msec for males and \>470 msec for females, and QRS duration. Any cardiac rhythm other than sinus rhythm that was interpreted by the Investigator was clinically significant.
| Participants | GBT021601+[14C]-GBT021601 |
|---|---|
| Number of Participants With Clinically Significant ECG Values | 0 |
Physical Examination test included body weight and height. physical examination was conducted at screening. Clinical significance was judged by investigator.
| Participants | GBT021601+[14C]-GBT021601 |
|---|---|
| Number of Participants With Clinically Significant Physical Examination Values | 0 |
Collected over From Day 1 up to maximum of Day 207. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GBT021601+[14C]-GBT021601 | 0/9 (0%) | 0/9 (0%) | 4/9 (44.4%) |
| Event | GBT021601+[14C]-GBT021601 |
|---|---|
| HeadacheNervous system disorders | 2/9 |
| NauseaGastrointestinal disorders | 1/9 |
| COVID-19Infections and infestations | 1/9 |
| Animal scratchInjury, poisoning and procedural complications | 1/9 |
| PolymenorrhoeaReproductive system and breast disorders | 1/9 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 1/9 |
Safety analysis set included all participants who had received 1 dose of GBT021601.
| Age, Continuous(Years) | GBT021601+[14C]-GBT021601 |
|---|---|
| Mean | 33.6 ± 7.42 |
| Sex: Female, Male(Participants) | GBT021601+[14C]-GBT021601 |
|---|---|
| Female | 2 |
| Male | 7 |
| Ethnicity (NIH/OMB)(Participants) | GBT021601+[14C]-GBT021601 |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 9 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | GBT021601+[14C]-GBT021601 |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 8 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Dec 2022 to primary completion in Aug 2023, 7 months.
Results were first posted in Jan 2025, 1 year 4 months after primary completion.
Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 7 months is below that.
Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osivelotor